Brain diffusion alterations in patients with COVID-19 pathology and neurological manifestations

被引:14
|
作者
Caroli, Anna [1 ]
Capelli, Serena [1 ]
Napolitano, Angela [2 ]
Cabrini, Giulia [3 ]
Arrigoni, Alberto [1 ]
Pezzetti, Giulio [2 ]
Previtali, Mattia [1 ]
Longhi, Luca Giovanni [4 ]
Zangari, Rosalia [5 ]
Lorini, Ferdinando Luca [6 ]
Sessa, Maria [7 ]
Remuzzi, Andrea [3 ]
Gerevini, Simonetta [2 ,8 ]
机构
[1] Ist Ric Farmacol Mario Negri IRCCS, Bioengn Dept, I-24020 Ranica, BG, Italy
[2] ASST Papa Giovanni XXIII, Dept Neuroradiol, I-24127 Bergamo, Italy
[3] Univ Bergamo, Dept Management Informat & Prod Engn, I-24044 Dalmine, BG, Italy
[4] ASST Papa Giovanni XXIII, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Bergamo, Italy
[5] ASST Papa Giovanni XXIII, FROM Res Fdn, I-24127 Bergamo, Italy
[6] ASST Papa Giovanni XXIII, Dept Emergency & Crit Care Area, Bergamo, Italy
[7] ASST Papa Giovanni XXIII, Dept Neurol, I-24127 Bergamo, Italy
[8] ASST Papa Giovanni XXIII, Dept Neuroradiol, Piazza OMS 1, I-24127 Bergamo, Italy
关键词
COVID-19; Diffusion weighted imaging; ADC; Neuroinflammation;
D O I
10.1016/j.nicl.2023.103338
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Background and objective: COVID-19 neurological manifestations have been progressively recognized. Among available MRI techniques, diffusion weighted imaging (DWI) shows promise to study microstructure, inflammation, and edema. Previous DWI studies reported alterations in brain diffusivity in COVID-19 patients, as assessed by morphologic evaluation of brain DWI scans only. The aim of this study was to assess and quantify brain diffusion alterations in COVID-19 patients with neurological manifestations. Methods: 215 COVID-19 patients with neurological manifestations (olfactory and/or other neurological disorders) and 36 normal controls were compared and studied with DWI and T1-weighted MRI scans. MRI scans were processed by a semi-automatic processing procedure specifically developed for the purpose of this study, and the Apparent Diffusion Coefficient (ADC) was quantified in different brain tissues and individual white matter (WM) and gray matter (GM) regions. Differences in ADC values were assessed between COVID-19 patients and normal controls, as well as in the COVID-19 patient population grouped by hospitalization and neurological symptoms. Results: Among COVID-19 patients (median [IQR] = 52 [42 - 60] years of age, 58 % females), 91 were hospitalized and 26 needed intensive care. 84 patients had hyposmia/ageusia only, while 131 ones showed other neurological disorders. COVID-19 patients showed significantly increased ADC values in the WM and in several GM regions (p < 0.001). ADC values were significantly correlated with MRI time from disease onset (p < 0.05). Hospitalized patients showed significantly higher ADC alteration than non-hospitalized patients in all brain tissues; similarly, COVID-19 patients with neurological disorders showed significantly higher ADC values than those with olfactory loss only. ADC alteration was highest in patients with cognitive or memory disorder and in those with encephalitis or meningitis. ADC values were neither associated with the duration of hospitalization nor with the need for intensive care.Conclusion: Current findings suggest DWI potential as a non-invasive marker of neuroinflammation in COVID-19, and the transient nature of the same. Future longitudinal studies are needed to confirm our findings.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19
    Tsagkaris, Christos
    Bilal, Muhammad
    Aktar, Irem
    Aboufandi, Youssef
    Tas, Ahmet
    Aborode, Abdullahi Tunde
    Suvvari, Tarun Kumar
    Ahmad, Shoaib
    Shkodina, Anastasiia
    Phadke, Rachana
    Emhamed, Marwa S.
    Baig, Atif Amin
    Alexiou, Athanasios
    Ashraf, Ghulam Md.
    Kamal, Mohammad Amjad
    [J]. CURRENT ALZHEIMER RESEARCH, 2022, 19 (09) : 641 - 657
  • [2] Neurological manifestations of COVID-19 – an approach to categories of pathology
    Yana Leven
    Julian Bösel
    [J]. Neurological Research and Practice, 3
  • [3] Brain cortical alterations in COVID-19 patients with neurological symptoms
    Sanabria-Diaz, Gretel
    Etter, Manina Maja
    Melie-Garcia, Lester
    Lieb, Johanna M. M.
    Psychogios, Marios-Nikos
    Hutter, Gregor
    Granziera, Cristina
    [J]. FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [4] Brain Biomarkers in Patients with COVID-19 and Neurological Manifestations: A Narrative Review
    Tyagi, Mayank
    Kapoor, Indu
    Mahajan, Charu
    Gupta, Nidhi
    Prabhakar, Hemanshu
    [J]. JOURNAL OF NEUROANAESTHESIOLOGY AND CRITICAL CARE, 2022, 09 (01) : 10 - 15
  • [5] Neurological Manifestations and COVID-19
    Costa, Andreia
    Silva-Pinto, Andre
    [J]. ACTA MEDICA PORTUGUESA, 2020, 33 (12): : 787 - 788
  • [6] Neurological Manifestations in COVID-19
    Koleva, Ts
    Titianova, E.
    Popov, G.
    Mutafchiyski, V
    [J]. NEUROSONOLOGY AND CEREBRAL HEMODYNAMICS, 2020, 16 (02): : 112 - 121
  • [7] Neurological Manifestations in COVID-19
    Wanjari, Rohit
    Joshi, Abhishek
    Mehendale, Ashok
    [J]. JOURNAL OF RESEARCH IN MEDICAL AND DENTAL SCIENCE, 2022, 10 (09): : 69 - 74
  • [8] Neurological Manifestations of COVID-19
    Alsharei, Alaa Salah A. G.
    Elbashir, Safaa
    [J]. WORLD FAMILY MEDICINE, 2022, 20 (08): : 70 - 73
  • [9] Neurological Manifestations of COVID-19
    Badii, Melody
    Poursheykhi, Meryim
    Shivaprasad, Akhil
    Smith, Robert
    Shroff, Sheetal
    [J]. NEUROLOGY, 2021, 96 (15)
  • [10] Neurological manifestations of COVID-19
    Kanwar, Dureshahwar
    Baig, Abdul Mannan
    Wasay, Mohammad
    [J]. JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2020, 70 (05) : S101 - S103